Evidence map›Paper›PMID 40733648›Full record

ArticleVaccines2025

Pu Wang, Gang Zhang, Yurong Cai, Lingling Jiang, Xiaoxia Niu, Sinong Zhang, Weifeng Gao, Zhiwei Wu, Yong Li

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pu WangSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.
Gang ZhangSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.
Yurong CaiSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.ORCID 0000-0002-4515-2484
Lingling JiangSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.
Xiaoxia NiuSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.
Sinong ZhangSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.
Weifeng GaoSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.
Zhiwei WuSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.ORCID 0000-0002-0672-948X
Yong LiSchool of Life Sciences, Ningxia University, Yinchuan 750021, China.ORCID 0000-0003-2036-9166

Funding

Nanjing University-Ningxia University Collaborative Project 2017BN04Ningxia Natural Science Foundation 2022AAC03077the Key Research and Development Program of Ningxia Hui Autonomous Region 2023BCF01038the National Natural Science Foundation of China U22A20525
6 · The paper itself

Abstract

BACKGROUND/

objectives

methodsThe

resultsZera-71CA-mCherry can be expressed in Sf9 cells, forming 0.5-1.2 μm protein bodies. Excising the mCherry sequence, Zera-71CA/Zera-PPE18 candidate nanoparticle-immunized mice were able to elicit serum antibody levels and the proliferation of splenic lymphocytes, and immunized calves were determined to have high levels of serum antibody levels, and IFN-γ and TNF-α levels.

conclusionsThe results indicated that Zera-71CA/Zera-PPE18 recombinant nanoparticles had good immunogenicity as a subunit vaccine in both BALB/c mice and calves and are potential candidates for further development as effective subunit vaccines.

Indexed as

immunityMycobacterium tuberculosisPPE18vaccineZera nanoparticles

Identifiers

PMID40733648
PMCPMC12300796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.